AstraZeneca

BRISTOL-MYERS SQUIBB CO BRISTOL MYERS SQUIBB0R1F · PharmaceuticalsNew York City, United States

70% matchPublic

Bristol-Myers Squibb Company is a global biopharmaceutical enterprise engaged in the discovery, development, manufacturing, and commercialization of pharmaceutical products. Its extensive portfolio of medicines targets a wide array of serious medical conditions, including those in the fields of hematology, oncology, cardiovascular health, immunology, fibrotic disorders, neuroscience, and COVID-19. The company's prominent therapies include Revlimid, an oral immunomodulator prescribed for multiple myeloma; Eliquis, an oral inhibitor used to lower the risk of stroke/systemic embolism in non-valvular atrial fibrillation and to treat deep vein thrombosis/pulmonary embolism; and Opdivo, a key anti-cancer agent. Additional significant products are Pomalyst/Imnovid for multiple myeloma; Orencia, which addresses active rheumatoid arthritis and psoriatic arthritis; and Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia. Its lineup further features Yervoy for unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy; Reblozyl for adult patients experiencing anemia due to beta thalassemia; and Empliciti, also for multiple myeloma. Recent innovations include Zeposia for relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for specific types of B-cell lymphoma; Inrebic, an oral kinase inhibitor for myelofibrosis; and Onureg for adult patients with acute myeloid leukemia. Bristol-Myers Squibb distributes its pharmaceutical offerings to a broad network of customers, encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and various government agencies. The organization, established in 1887 and previously known as Bristol-Myers Company, is headquartered in New York, New York.

Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.

協和キリン4151 · PharmaceuticalsTokyo, Japan

68% matchPublic

Operating globally, Kyowa Kirin Co., Ltd. is a pharmaceutical company focused on the discovery, development, manufacturing, and marketing of innovative medical therapies. The company's core areas of expertise span oncology, nephrology, central nervous system disorders, and immunology. Its extensive product portfolio includes established medications such as ABSTRAL, a sublingual fentanyl formulation for managing breakthrough pain in cancer patients; ALLELOCK, an antihistamine for various allergic conditions; and CONIEL, a calcium channel blocker prescribed for hypertension and angina. Kyowa Kirin also provides a range of advanced biological and specialized treatments. These encompass Crysvita, a recombinant human monoclonal IgG1 antibody targeting fibroblast growth factor 23, and blood-related therapies like ESPO (human erythropoietin), NESP (an erythropoiesis stimulating agent), and GRAN (a human colony-stimulating factor). Further products in its lineup address diverse medical needs: G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for opioid-induced constipation; Nouriast/Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. Other significant offerings are PecFent, a nasally administered spray; POTELIGEO, a humanized monoclonal antibody targeting CC chemokine receptor 4; REGPARA for secondary hyperparathyroidism; Romiplate/Nplate, a recombinant protein promoting platelet production; and SANCUSO for managing nausea and vomiting. Beyond its current offerings, Kyowa Kirin is actively involved in pipeline development, notably through a strategic collaboration with Amgen Inc. for the joint development and commercialization of KHK4083. This Phase 3-ready, fully human anti-OX40 monoclonal antibody is being developed to treat atopic dermatitis. Established in Tokyo, Japan, in 1949, the company changed its name from Kyowa Hakko Kirin Co., Ltd. to Kyowa Kirin Co., Ltd. in June 2019. It operates as a subsidiary of Kirin Holdings Company, Limited.

GSK PLC LS-,3125GS71 · PharmaceuticalsGermany

68% matchPublic

GSK is a biopharmaceutical company that discovers, develops, and delivers medicines and vaccines for patients globally. Its research and development efforts focus on four primary therapeutic areas: respiratory, immunology and inflammation, oncology, HIV, and infectious diseases.

Boehringer IngelheimPharmaceuticalsGermany

68% match

Boehringer Ingelheim is a privately held pharmaceutical company that develops and manufactures prescription medicines for human healthcare, including therapies in areas such as cardiovascular, respiratory, metabolic, immunology and oncology. It also provides animal-health medicines and vaccines through its Boehringer Ingelheim Animal Health business, serving healthcare professionals, patients and veterinary customers worldwide.

Nxera Pharma Co., Ltd., established in Tokyo, Japan, in 1990, is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of pharmaceutical solutions. The company's operations extend across multiple international markets, including Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its array of commercially available products encompasses respiratory treatments like Ultibro/Breezhaler and Seebri/Breezhaler for chronic obstructive pulmonary disease, as well as Enerzair and Breezhaler to manage asthma. Other marketed therapeutics include ORAVI, a unique formulation addressing oropharyngeal candidiasis, and PIVLAZ, prescribed for cerebral vasospasm. The firm boasts a robust pipeline of investigational medicines, featuring HTL0039732 for immuno-oncology, HTL0048149 for schizophrenia, Daridorexant targeting insomnia, and HTL0016878 for both schizophrenia and other neuropsychiatric conditions. Additional compounds under development include PF-07081532 for Type 2 diabetes mellitus and obesity, PF-07054894 for inflammatory bowel disease, PF-07258669 for anorexia, and PF-06954522 for metabolic disorders. The pipeline also contains NBI-1117569 for various neurological diseases and NBI-1117570 for central nervous system ailments. Furthermore, Nxera Pharma is advancing a GPR35 agonist in the preclinical stage for inflammatory bowel disease and other gastrointestinal conditions, alongside other early-stage drug candidates. The company maintains significant strategic collaborations with industry leaders such as AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily.